Form D · Biotechnology
Audentes Therapeutics, Inc.
San Francisco, CA · CIK 0001628738
Offering snapshot reported Oct 22, 2015 · SEC filing
- Reported sold
- $65M Offering amount: $65M
- Investors reported
- 27 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 8, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 22, 2015 | Initial | $64,999,949 | No comparison | 27 | SEC filing |
| Sep 2, 2015 | Initial | $0 | No comparison | 21 | SEC filing |
| Dec 24, 2014 | Initial | $42,500,002 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-249874
Source: Form D, filed Oct 22, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Louis Lange | Director |
| Jonathan Leff | Director |
| Kush Parmar | Director |
| Matthew Patterson | Director, Executive |
| Thomas Schuetz | Director |
| Jonathan Silverstein | Director |
| Jonathan S Ilverstein | Director |
| Steve Squinto | Director |
| Thomas Woiwode | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
101 Montgomery Street, Suite 2650
San Francisco, CA, 94104
San Francisco, CA, 94104